{"id":510440,"date":"2021-07-07T11:03:57","date_gmt":"2021-07-07T15:03:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\/"},"modified":"2021-07-07T11:03:57","modified_gmt":"2021-07-07T15:03:57","slug":"athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\/","title":{"rendered":"Athira Pharma Investor Alert: Goldman Scarlato &amp; Penny Investor Rights Lawyers Evaluate Potential Individual, Non-Class Action Claims on Behalf of ATHA Investors"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">PHILADELPHIA<\/span> and <span class=\"xn-location\">CLEVELAND<\/span>, <span class=\"xn-chron\">July 7, 2021<\/span> \/PRNewswire\/ &#8212; The investor rights attorneys at Goldman Scarlato &amp; Penny, PC law firm (&#8220;GSP&#8221;) are evaluating potential claims for compensation on behalf of investors who purchased Athira Pharma\u00a0(Nasdaq: ATHA) shares either in its initial public offering (&#8220;IPO&#8221;) or its private placements and suffered losses. The GSP attorneys plan to primarily seek compensation for Athira investors individually, rather than in a class action. Each investor&#8217;s situation must be individually evaluated before representation is offered. Not all investors may qualify for individual representation.<\/p>\n<p>Athira Pharma is a biopharmaceutical company founded in 2011, with a declared focus on drugs targeting neurological diseases. In <span class=\"xn-chron\">September 2020<\/span>, Athira Pharma published a Prospectus offering 12,000,000 shares approved for listing on Nasdaq at <span class=\"xn-money\">$17<\/span> per share.<\/p>\n<p>In <span class=\"xn-chron\">June 2021<\/span>, Athira Pharma announced placing its CEO <span class=\"xn-person\">Leen Kawas<\/span> on temporary leave pending investigation into Dr. Kawas&#8217;s doctoral research conducted while at <span class=\"xn-org\">Washington State University<\/span>. Reports indicate the investigation concerns alleged use of manipulated images in several papers authored by Athira&#8217;s former CEO. The announcement caused a price decline, closing at <span class=\"xn-money\">$11.15<\/span> on <span class=\"xn-chron\">June 18, 2021<\/span>. As of <span class=\"xn-chron\">June 6, 2021<\/span> the price per share is <span class=\"xn-money\">$10.84<\/span>.<\/p>\n<p>\n        <b>ATHA Investors May Be Able to Pursue Individual Claims<\/b>\n      <\/p>\n<p>Investor rights attorneys <span class=\"xn-person\">Alan Rosca<\/span> and <span class=\"xn-person\">Paul Scarlato<\/span> have been investigating certain alleged misrepresentations and omissions by Athira Pharma in connection with its IPO or private placements, and are preparing to take action on behalf of some of the ATHA investors and seek compensation for their losses, separately from any pending class action. Investors in Athira Pharma interested in filing individual claims may contact attorneys\u00a0Rosca or\u00a0Scarlato for a free, no-obligation evaluation of their options at 888-998-0530,\u00a0<a target=\"_blank\" href=\"mailto:rosca@lawgsp.com\" rel=\"nofollow noopener\">rosca@lawgsp.com<\/a>\u00a0or by leaving a message on <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3220076-1&amp;h=4050897778&amp;u=https%3A%2F%2Finvestorlawyers.org%2Fathira-pharma-investor-center&amp;a=https%3A%2F%2Finvestorlawyers.org%2Fathira-pharma-investor-center\" rel=\"nofollow noopener\">https:\/\/investorlawyers.org\/athira-pharma-investor-center<\/a>.<\/p>\n<p>The GSP investor rights attorneys have decades of combined experience representing investors who lost money as a\u00a0result of investment misconduct. They take most cases of this type on a contingency fee basis and advance the case costs. There are no fees or costs if no recovery.<\/p>\n<p>Visit <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3220076-1&amp;h=1210137780&amp;u=https%3A%2F%2Finvestorlawyers.org%2F&amp;a=https%3A%2F%2Finvestorlawyers.org\" rel=\"nofollow noopener\">https:\/\/investorlawyers.org<\/a>\u00a0for more information about the firm and GSP attorneys&#8217; background and admissions to practice law. This release may be deemed to include Attorney Advertising. There has been no finding of liability as to the allegations herein. \u00a9 GSP 2021.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH35150&amp;sd=2021-07-07\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/athira-pharma-investor-alert-goldman-scarlato--penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors-301327078.html\">https:\/\/www.prnewswire.com\/news-releases\/athira-pharma-investor-alert-goldman-scarlato&#8211;penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors-301327078.html<\/a><\/p>\n<p>SOURCE  Goldman Scarlato &amp; Penny, P.C.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PH35150&amp;Transmission_Id=202107071100PR_NEWS_USPR_____PH35150&amp;DateId=20210707\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire PHILADELPHIA and CLEVELAND, July 7, 2021 \/PRNewswire\/ &#8212; The investor rights attorneys at Goldman Scarlato &amp; Penny, PC law firm (&#8220;GSP&#8221;) are evaluating potential claims for compensation on behalf of investors who purchased Athira Pharma\u00a0(Nasdaq: ATHA) shares either in its initial public offering (&#8220;IPO&#8221;) or its private placements and suffered losses. The GSP attorneys plan to primarily seek compensation for Athira investors individually, rather than in a class action. Each investor&#8217;s situation must be individually evaluated before representation is offered. Not all investors may qualify for individual representation. Athira Pharma is a biopharmaceutical company founded in 2011, with a declared focus on drugs targeting neurological diseases. In September 2020, Athira Pharma published a Prospectus offering 12,000,000 shares approved &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Athira Pharma Investor Alert: Goldman Scarlato &amp; Penny Investor Rights Lawyers Evaluate Potential Individual, Non-Class Action Claims on Behalf of ATHA Investors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-510440","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Athira Pharma Investor Alert: Goldman Scarlato &amp; Penny Investor Rights Lawyers Evaluate Potential Individual, Non-Class Action Claims on Behalf of ATHA Investors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Athira Pharma Investor Alert: Goldman Scarlato &amp; Penny Investor Rights Lawyers Evaluate Potential Individual, Non-Class Action Claims on Behalf of ATHA Investors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire PHILADELPHIA and CLEVELAND, July 7, 2021 \/PRNewswire\/ &#8212; The investor rights attorneys at Goldman Scarlato &amp; Penny, PC law firm (&#8220;GSP&#8221;) are evaluating potential claims for compensation on behalf of investors who purchased Athira Pharma\u00a0(Nasdaq: ATHA) shares either in its initial public offering (&#8220;IPO&#8221;) or its private placements and suffered losses. The GSP attorneys plan to primarily seek compensation for Athira investors individually, rather than in a class action. Each investor&#8217;s situation must be individually evaluated before representation is offered. Not all investors may qualify for individual representation. Athira Pharma is a biopharmaceutical company founded in 2011, with a declared focus on drugs targeting neurological diseases. In September 2020, Athira Pharma published a Prospectus offering 12,000,000 shares approved &hellip; Continue reading &quot;Athira Pharma Investor Alert: Goldman Scarlato &amp; Penny Investor Rights Lawyers Evaluate Potential Individual, Non-Class Action Claims on Behalf of ATHA Investors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-07T15:03:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH35150&amp;sd=2021-07-07\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Athira Pharma Investor Alert: Goldman Scarlato &amp; Penny Investor Rights Lawyers Evaluate Potential Individual, Non-Class Action Claims on Behalf of ATHA Investors\",\"datePublished\":\"2021-07-07T15:03:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\\\/\"},\"wordCount\":413,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH35150&amp;sd=2021-07-07\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\\\/\",\"name\":\"Athira Pharma Investor Alert: Goldman Scarlato &amp; Penny Investor Rights Lawyers Evaluate Potential Individual, Non-Class Action Claims on Behalf of ATHA Investors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH35150&amp;sd=2021-07-07\",\"datePublished\":\"2021-07-07T15:03:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH35150&amp;sd=2021-07-07\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH35150&amp;sd=2021-07-07\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Athira Pharma Investor Alert: Goldman Scarlato &amp; Penny Investor Rights Lawyers Evaluate Potential Individual, Non-Class Action Claims on Behalf of ATHA Investors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Athira Pharma Investor Alert: Goldman Scarlato &amp; Penny Investor Rights Lawyers Evaluate Potential Individual, Non-Class Action Claims on Behalf of ATHA Investors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\/","og_locale":"en_US","og_type":"article","og_title":"Athira Pharma Investor Alert: Goldman Scarlato &amp; Penny Investor Rights Lawyers Evaluate Potential Individual, Non-Class Action Claims on Behalf of ATHA Investors - Market Newsdesk","og_description":"PR Newswire PHILADELPHIA and CLEVELAND, July 7, 2021 \/PRNewswire\/ &#8212; The investor rights attorneys at Goldman Scarlato &amp; Penny, PC law firm (&#8220;GSP&#8221;) are evaluating potential claims for compensation on behalf of investors who purchased Athira Pharma\u00a0(Nasdaq: ATHA) shares either in its initial public offering (&#8220;IPO&#8221;) or its private placements and suffered losses. The GSP attorneys plan to primarily seek compensation for Athira investors individually, rather than in a class action. Each investor&#8217;s situation must be individually evaluated before representation is offered. Not all investors may qualify for individual representation. Athira Pharma is a biopharmaceutical company founded in 2011, with a declared focus on drugs targeting neurological diseases. In September 2020, Athira Pharma published a Prospectus offering 12,000,000 shares approved &hellip; Continue reading \"Athira Pharma Investor Alert: Goldman Scarlato &amp; Penny Investor Rights Lawyers Evaluate Potential Individual, Non-Class Action Claims on Behalf of ATHA Investors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-07T15:03:57+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH35150&amp;sd=2021-07-07","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Athira Pharma Investor Alert: Goldman Scarlato &amp; Penny Investor Rights Lawyers Evaluate Potential Individual, Non-Class Action Claims on Behalf of ATHA Investors","datePublished":"2021-07-07T15:03:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\/"},"wordCount":413,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH35150&amp;sd=2021-07-07","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\/","name":"Athira Pharma Investor Alert: Goldman Scarlato &amp; Penny Investor Rights Lawyers Evaluate Potential Individual, Non-Class Action Claims on Behalf of ATHA Investors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH35150&amp;sd=2021-07-07","datePublished":"2021-07-07T15:03:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH35150&amp;sd=2021-07-07","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH35150&amp;sd=2021-07-07"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-investor-alert-goldman-scarlato-penny-investor-rights-lawyers-evaluate-potential-individual-non-class-action-claims-on-behalf-of-atha-investors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Athira Pharma Investor Alert: Goldman Scarlato &amp; Penny Investor Rights Lawyers Evaluate Potential Individual, Non-Class Action Claims on Behalf of ATHA Investors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510440","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=510440"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510440\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=510440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=510440"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=510440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}